Unlock the Editor’s Digest free of charge
Flo Well being has pulled in $200mn from non-public fairness agency Normal Atlantic to change into the primary totally digital feminine well being start-up valued at greater than $1bn as traders faucet into the rising marketplace for fertility and menopause merchandise.
The world’s largest interval and fertility tracker by consumer numbers will put the funding in the direction of constructing options reminiscent of symptom evaluation for the estimated 450mn girls worldwide, based on McKinsey, who expertise perimenopausal or menopausal signs yearly.
The UK-based app intends to “ship probably the most personalised expertise for customers of all ages and demographics”, together with the “untapped” space of ladies experiencing perimenopause and menopause, chief govt Dmitry Gurski advised the Monetary Occasions.
Focusing on these customers was “the pure subsequent step” for Flo, which beforehand solely addressed customers who nonetheless menstruate, mentioned Anna Klepchukova, the corporate’s chief medical officer.
Traders are lastly waking as much as the potential of the $36bn market — as estimated by Dealroom — for girls’s healthcare, which researchers say has beforehand suffered from a dearth of analysis and years of under-investment.
Funding for start-ups particularly focusing on feminine healthcare grew 5 per cent between 2022 and 2023, defying a broader downturn in well being funding, based on evaluation by Deloitte of PitchBook knowledge.
Normal Atlantic’s principal Jessie Cai and managing director Tanzeen Syed will be part of Flo’s board of administrators as a part of the transaction. The non-public fairness group is thought for beforehand backing fast-growing know-how firms together with Alibaba, Fb, and ByteDance.
London-headquartered Flo, which was co-founded by Dmitry and Yuri Gurski in Belarus in 2015, mentioned it had practically 5mn paid subscribers as of final month. It expects its revenues from subscriptions, which fluctuate by area however begin at £4.99 month-to-month within the UK, to exceed $200mn this 12 months.
Flo is the most recent start-up looking for to faucet into the rising marketplace for menopause and perimenopause therapeutics. The sector has grown quickly in recent times as discussions about menopause have change into extra mainstream.
“Individuals are fascinated about it, speaking about it, and investing in it,” mentioned Elizabeth Bailey, co-founder of specialist enterprise capital fund RH Capital.
Flo attracted consideration in September 2022 when it launched a free “nameless mode” after the US Supreme Courtroom overturned girls’s constitutional proper to abortion and catapulted privateness considerations to centre stage. The setting offers customers the facility to log and analyse their signs with out linking any intimate knowledge to their title.
Flo’s replace, nevertheless, solely got here after the corporate acquired a public reprimand and agreed to enhance its product in 2021 following an investigation from the US Federal Commerce Fee over allegations it had shared knowledge on customers’ menstrual cycles and pregnancies with analytics groups at third-party firms, together with Google and Fb.
Energetic customers on Flo slipped instantly after the Supreme Courtroom ruling as fears escalated that girls’s private knowledge might be used to incriminate them in the event that they sought an abortion. The numbers have since returned to development, based on Sensor Tower.
Flo mentioned it had 70mn month-to-month lively customers as of June 2024, increased than Sensor Tower’s determine of 39mn.
Flo’s rivals embody sexual wellness app Rosy, which introduced in Could that it was increasing its companies to focus on menopause, in addition to endometriosis and fibroids.
Interval and fertility tracker Clue, in the meantime, launched a perimenopause mode in September so customers may log signs reminiscent of scorching flushes, sleep modifications and temper.